Company News

Latest News

Polaris Phase II Soft Tissue Sarcoma Trial Receives Attention with ASCO Invitation to Present Results
2021/04/04-Polaris Group Polaris Pharmaceuticals-KY(6550TW) announces, Due to the impressive results...
Read more »
Polaris Phase III interim analysis of lung mesothelioma study showed a chance of greater than 80% for success at the end of study
Based on the data at the interim analysis of Feb 25, 2021, it is estimated that the chance for success,...
Read more »
Polaris lung cancer clinical trial phase III analysis reached the highest standard, and drug certification is imminent
Polaris Group (TW:6550) released its interim analysis report for the Phase III clinical trial of pleural...
Read more »
Polaris Group signs collaboration agreement with Nanotein Technologies, Inc.
Nanotein Technologies, Inc., an innovative startup biotechnology company in the San Francisco Bay Area,...
Read more »
Polaris announces to enroll the first patient of Phase IB Clinical Trial in GBM
Taipei, September 17, 2020 – Polaris Group announced today that the first patient has been dosed in a...
Read more »
1 … 4 5 6
Scroll to Top
This site is registered on wpml.org as a development site.